|
|
Volumn 35, Issue 22, 2017, Pages
|
|
HELOISE: Phase IIIb randomized multicenter study comparing standard-of-care and higher-dose trastuzumab regimens combined with chemotherapy as first-line therapy in patients with human epidermal growth factor receptor 2–positive metastatic gastric or gastroesophageal junction adenocarcinoma
a
e
Roche China Ltd
(China)
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
CAPECITABINE;
CISPLATIN;
EPIDERMAL GROWTH FACTOR RECEPTOR 2;
TRASTUZUMAB;
ANTINEOPLASTIC AGENT;
ERBB2 PROTEIN, HUMAN;
ADULT;
ANEMIA;
ARTICLE;
CANCER COMBINATION CHEMOTHERAPY;
CANCER GROWTH;
COMPARATIVE STUDY;
CONCENTRATION (PARAMETERS);
CONGESTIVE HEART FAILURE;
CONTINUOUS INFUSION;
CONTROLLED STUDY;
DRUG EFFICACY;
DRUG MEGADOSE;
DRUG SAFETY;
FEMALE;
FOLLOW UP;
GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA;
HUMAN;
LOADING DRUG DOSE;
MAINTENANCE DRUG DOSE;
MAJOR CLINICAL STUDY;
MALE;
MULTICENTER STUDY;
MULTIPLE CYCLE TREATMENT;
NAUSEA;
NEUTROPENIA;
OVERALL SURVIVAL;
PHASE 3 CLINICAL TRIAL;
POSITIVE METASTATIC GASTRIC ADENOCARCINOMA;
PRIORITY JOURNAL;
PROGRESSION FREE SURVIVAL;
RANDOMIZED CONTROLLED TRIAL;
STOMACH ADENOCARCINOMA;
VOMITING;
ADENOCARCINOMA;
AGED;
BLOOD;
CHEMISTRY;
CLINICAL TRIAL;
DISEASE COURSE;
GASTROESOPHAGEAL JUNCTION;
HEALTH CARE QUALITY;
MIDDLE AGED;
PATHOLOGY;
SECONDARY;
STOMACH NEOPLASMS;
SURVIVAL RATE;
VERY ELDERLY;
ADENOCARCINOMA;
ADULT;
AGED;
AGED, 80 AND OVER;
ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;
CAPECITABINE;
CISPLATIN;
DISEASE PROGRESSION;
ESOPHAGOGASTRIC JUNCTION;
FEMALE;
HUMANS;
MALE;
MIDDLE AGED;
RECEPTOR, ERBB-2;
STANDARD OF CARE;
STOMACH NEOPLASMS;
SURVIVAL RATE;
TRASTUZUMAB;
|
|
EID: 85026757787
PISSN: 0732183X
EISSN: 15277755
Source Type: Journal
DOI: 10.1200/JCO.2016.71.6852 Document Type: Article |
|
Times cited : (106)
|
|
References (14)
|
